Hayat Pharmaceutical Industries Faces Declining Performance Amid Market Position Shift

Hayat Pharmaceutical Industries Co. has recently undergone an adjustment in evaluation, reflecting a shift in its market position and performance indicators. The company, operating within the Pharmaceuticals & Biotechnology sector, has been noted for its low Return on Capital Employed (ROCE) of 13.28%, indicating challenges in profitability relative to its total capital. Additionally, the Return on Equity (ROE) stands at 6.24%, suggesting limited returns for shareholders. Over the past five years, Hayat has experienced a decline in growth, with net sales decreasing at an annual rate of 0.78% and operating profit declining by 13.86%. The latest financial results for June 2026 show a net profit of JOD 1.71 million, which has contracted by 38.12%. Despite being net-debt free, the company has struggled to keep pace with market performance, generating a return of 5.69% over the past year, significantly trailing the Jordan General Index's return of 34.01%. This evaluation adjustment highlights the underlying trends affecting Hayat Pharmaceutical Industries Co., emphasizing the need for strategic improvements in management efficiency and growth initiatives. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.